Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

SkinBioTherapeutics CEO on strong 2025 growth as new deals add momentum

9:07
 
Share
 

Manage episode 522856291 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
SkinBioTherapeutics PLC (AIM:SBTX) CEO Stuart Ashman talked with Proactive's Stephen Gunnion about the company's strong financial and strategic progress in 2025. Ashman highlighted a 284% increase in revenue to £4.6 million, a 319% rise in gross profit, and a 62% reduction in operating losses, noting the results were in line with market expectations. He said, “We’ve achieved pretty much exactly what was expected by the market.” The company advanced its five-pillar skin health strategy, with particular developments in cosmetics and gut-skin axis supplements. Its cosmetic ingredient SkinBiotix, branded as Zenakine by partner Croda, launched in April and is generating strong industry interest, including winning an award at the In-Cosmetics Asia event. Additionally, AxisBiotix products targeting acne and psoriasis were launched through an exclusive two-year deal with Superdrug, now available in 180 stores with plans for wider rollout. SkinBioTherapeutics also progressed its acquisition strategy, integrating Dermonix and Bio-Tech Solutions. Ashman noted these contributed meaningful revenue and manufacturing capability, strengthening internal operations and product development. Looking ahead, the company expects £6.2 million in revenue and £700,000 in adjusted EBITDA for the next financial year, maintaining confidence in future growth. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications to stay up to date. ` #SkinBioTherapeutics #SkinHealth #Biotech #Croda #Zenakine #AxisBiotix #Dermonix #Superdrug #SkincareInnovation #Microbiome #LifeSciences #InvestorUpdate #ProactiveInvestors
  continue reading

611 episodes

Artwork
iconShare
 
Manage episode 522856291 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
SkinBioTherapeutics PLC (AIM:SBTX) CEO Stuart Ashman talked with Proactive's Stephen Gunnion about the company's strong financial and strategic progress in 2025. Ashman highlighted a 284% increase in revenue to £4.6 million, a 319% rise in gross profit, and a 62% reduction in operating losses, noting the results were in line with market expectations. He said, “We’ve achieved pretty much exactly what was expected by the market.” The company advanced its five-pillar skin health strategy, with particular developments in cosmetics and gut-skin axis supplements. Its cosmetic ingredient SkinBiotix, branded as Zenakine by partner Croda, launched in April and is generating strong industry interest, including winning an award at the In-Cosmetics Asia event. Additionally, AxisBiotix products targeting acne and psoriasis were launched through an exclusive two-year deal with Superdrug, now available in 180 stores with plans for wider rollout. SkinBioTherapeutics also progressed its acquisition strategy, integrating Dermonix and Bio-Tech Solutions. Ashman noted these contributed meaningful revenue and manufacturing capability, strengthening internal operations and product development. Looking ahead, the company expects £6.2 million in revenue and £700,000 in adjusted EBITDA for the next financial year, maintaining confidence in future growth. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications to stay up to date. ` #SkinBioTherapeutics #SkinHealth #Biotech #Croda #Zenakine #AxisBiotix #Dermonix #Superdrug #SkincareInnovation #Microbiome #LifeSciences #InvestorUpdate #ProactiveInvestors
  continue reading

611 episodes

Все серии

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play